Apricus Biosciences Announces the Launch of Vitaros® for the Treatment of Erectile Dysfunction in Lebanon by Elis Pharmaceuticals Pharmaceutical Investing
Immunomedics Announces Achievement of Patient Enrollment Into Single-Arm Phase 2 Study With Sacituzumab Govitecan (IMMU-132) in Triple-Negative Breast Cancer Life Science Investing
Protalix BioTherapeutics Receives Confirmation of Order for over $24 Million of alfataliglicerase Life Science Investing
Capnia and Essentialis Announce Merger to Create Rare Disease Therapeutics Company Life Science Investing
RedHill Biopharma Announces Closing of Concurrent Public Offering and Registered Direct Offering of its American Depositary Shares and Warrants and Partial Exercise of the Option of Underwriters Life Science Investing
Progenics Pharmaceuticals Announces Independent Committee’s Positive Recommendation for Continuation of Phase 3 Clinical Trial of SPECT/CT Imaging Agent 1404 Pharmaceutical Investing
Vifor Pharma and Chemocentryx Announce Expansion of Kidney Health Alliance to Include CCX140 Pharmaceutical Investing
